EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

por Chaudry, M A, Sales, K, Ruf, P, Lindhofer, H, Winslet, M C
Publicado 2007

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

por Ruf, P, Gires, O, Jäger, M, Fellinger, K, Atz, J, Lindhofer, H
Publicado 2007

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

por Zeidler, R, Mysliwietz, J, Csánady, M, Walz, A, Ziegler, I, Schmitt, B, Wollenberg, B, Lindhofer, H
Publicado 2000

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado 2016